Rivastigmine
Product Images NDC 51956-0002

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 51956-0002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 01)

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 02)

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 03)

This appears to be a graph displaying the levels of Rivastigmine in ng/mL for three different dosages of the medication (4.6mg/24 hours, 9.5mg/24 hours, and 13.3mg/24 hours) based on the sample size of 22 individuals for each dose. The X-axis seems to represent the different values for Rivastigmine in ng/mL, while the Y-axis likely represents the number of individuals who had that level of the medication in their system.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 04)

This text appears to be a data table showing the change in ADAS-Cog rating from baseline for different treatment groups at different time points. The treatment groups include a medication containing 17.4 mg/24 hours, a medication containing 9.5 mg/24 hours taken twice daily, and a placebo group. The table also includes information on clinical improvement or decline.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 05)

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 06)

This is a description of the clinical improvement and decline observed in patients with the use of Rivastigmine Transdermal System, in two strengths (133 mg/24 hr and 9.5 mg/24 hr) during a period of 52 weeks of treatment. The graph shows better results in the group treated with the higher dose of the medication.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 07)

This seems to be a graph showing the clinical improvement of a treatment with two different strengths of Rivastigmine Transdermal System over weeks of treatment. The y-axis represents clinical improvement and the x-axis represents weeks of treatment. The graph shows that the 13.3 mg/24 hr treatment resulted in greater improvement than the 9.5 mg/24 hr treatment at a statistically significant level (p<0.05).*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 08)

This appears to be a report of a clinical trial that tested the effects of two different dosages of a transdermal system containing rivastigmine on some clinical outcome. The results are presented as LS (least squares) mean differences with their 95% confidence intervals indicating that only the highest dose resulted in statistically significant improvement. The report also shows the mean change over time in the outcome measure for each treatment group.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 09)

This appears to be a statistical analysis report of a clinical trial evaluating the effectiveness of Rivasligmine Transdermal System for clinical improvement over 16 weeks of treatment. The report includes mean differences, confidence intervals, and statistical significance levels for LS means. The data suggests that there was a clinical improvement with the treatment compared to a decline, with the higher dosage (13.3 mg/24 hr) showing the most improvement.*

FDA Label Image

Figure A (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 10)

The text describes a pouch containing a medicine called "Rivastigmine Transdermal System". It is intended for transdermal use and contains one system. The system consists of protective liners, a medicine adhesive, and an outside backing. Any other information is not available.*

FDA Label Image

Figure B (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 11)

The text appears to be a partial list of body parts with checkboxes to select left or right side. It is not clear what the purpose of this list is, so a more specific description cannot be provided.*

FDA Label Image

Figure C (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 12)

FDA Label Image

Figure D (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 13)

FDA Label Image

Figure E (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 14)

This text refers to "protective liners" which could be used to cover and protect a sticky surface of a transdermal system, such as a medical patch or adhesive bandage. However, without more context it is unclear what specific type of protective liner is being referred to or what material it is made of.*

FDA Label Image

Figure F (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 15)

FDA Label Image

Figure G (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 16)

FDA Label Image

Figure H (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 17)

FDA Label Image

Figure I (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 18)

This is a set of instructions on how to dispose of a slide folded patch. The patch should be placed in the trash. First, fold the sticky sides together and then place it in an empty pouch that you have saved. It is recommended to keep the pouch away from children and pets.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 19)

This is a pharmaceutical product with the name Rivastigmine Transdermal System. It is a transdermal drug delivery system (TDDS) containing 30 systems for transdermal use only. The NDC code is 51956-0001-7. The has produced partial or garbled information on the dosage delivery per system.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 20)

This is a medication label for a transdermal system that contains rivastigmine. Each system delivers an unknown amount of the medication, and the package contains 30 systems. Transdermal use is recommended.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 21)

This is a medication called Rivastigmine that is delivered through a transdermal system. The NDC number is 51956-0003-7 and it contains 30 systems. The text also includes some unreadable characters and symbols.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.